LOGIN
.jpg)
Combined & extended alendronate with teriparatide improves BMD in women with osteoporosis
November 2014
Combined & extended alendronate with teriparatide improves BMD in women with osteoporosis
Study Type:Randomized Trial
OE Level Evidence:2
Journal Level of Evidence:N/A
Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study
J Bone Miner Res. 2014 Aug;29(8):1777-85Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
125 postmenopausal women with osteoporosis who had undergone 9 months of teriparatide monotherapy were randomized to three treatment groups. Patients were allocated to either (1) continued 9 months combined teriparatide/alendronate therapy followed by 12 months extended alendronate; (2) continued 9 months combined teriparatide/raloxifene followed by 12 months extended raloxifene, or (3) continued ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.